Pharmacoeconomics of Low molecular Weight Heparin in Unstable Angina: A Critical Review
Economics assessment basically deals with science of drug cost, benefits and hope of survival in patients suffering from serious disease. This review focuses of the pharmacoeconomical factors associated with the use of low molecular weight heparin (LMWH) in unstable angina. Unsatble angina (UA) or non ST elevated myocardial infarction (NSTEMI) is one of common ischemic manifestation of acute coronary syndrome (ACS) and a large cause of hospitalization. The purpose of this article is to review and evaluate the available literatures on economic assessment of low molecular weight heparin (LMWH) over unfractionated heparin (UFH) in the management of unstable angina to establish their role in reducing therapy load, improve the effectiveness of care, optimize patient outcomes and overall cost of care by focusing on the most effective strategies. Economic analysis consistently demonstrated the efficacy of enoxaparin (LMWH) in reducing cardiovascular events and mortality in UA/NSTEMI. Investigators concluded that high cost of enoxaparin for the treatment of unstable angina was offset by the savings and cost effectiveness associated with fewer hospital admissions, less coagulation monitoring (aPTT), reduce frequency of death, myocardial infarction (MI) and invasive procedures such as catheterization and angioplasty compared to UFH.
- There are currently no refbacks.
International Journal of Basic Medical Sciences and Pharmacy (IJBMSP): ISSN: 2049-4963